Cutera® Announces Third Quarter 2024 Financial Results
Cutera (CUTR) reported Q3 2024 financial results with consolidated revenue of $32.5 million, representing a 30% decrease compared to Q3 2023. The company maintained cash and equivalents of $59.0 million. AviClear showed 16% growth year-over-year in international markets, while global core capital grew 7% sequentially. Gross profit was $1.8 million (6% of revenue), down from $6.5 million (14%) in Q3 2023. Operating loss was $36.2 million. Management reaffirmed full-year revenue guidance of $140-145 million and year-end 2024 cash guidance of approximately $40 million.
Cutera (CUTR) ha riportato i risultati finanziari del terzo trimestre 2024 con un fatturato consolidato di 32,5 milioni di dollari, che rappresenta una diminuzione del 30% rispetto al terzo trimestre 2023. L'azienda ha mantenuto liquidità e equivalenti per 59,0 milioni di dollari. AviClear ha mostrato una crescita del 16% su base annua nei mercati internazionali, mentre il capitale globale è aumentato del 7% rispetto al trimestre precedente. L'utile lordo è stato di 1,8 milioni di dollari (6% del fatturato), in calo rispetto ai 6,5 milioni di dollari (14%) nel terzo trimestre 2023. La perdita operativa è stata di 36,2 milioni di dollari. La direzione ha confermato le previsioni di fatturato per l'intero anno tra 140 e 145 milioni di dollari e la previsione di liquidità a fine 2024 di circa 40 milioni di dollari.
Cutera (CUTR) informó los resultados financieros del tercer trimestre de 2024 con ingresos consolidados de 32.5 millones de dólares, lo que representa una disminución del 30% en comparación con el tercer trimestre de 2023. La empresa mantuvo efectivo y equivalentes de 59.0 millones de dólares. AviClear mostró un crecimiento del 16% interanual en los mercados internacionales, mientras que el capital global básico creció un 7% de manera secuencial. La ganancia bruta fue de 1.8 millones de dólares (6% de los ingresos), frente a 6.5 millones de dólares (14%) en el tercer trimestre de 2023. La pérdida operativa fue de 36.2 millones de dólares. La dirección reafirmó la guía de ingresos para todo el año de entre 140 y 145 millones de dólares y la guía de efectivo para finales de 2024 de aproximadamente 40 millones de dólares.
Cutera (CUTR)는 2024년 3분기 재무 결과를 보고하며, 총 수익이 3천 250만 달러로 나타났으며, 이는 2023년 3분기 대비 30% 감소한 수치입니다. 회사는 5천 900만 달러의 현금 및 현금성 자산을 유지하고 있습니다. AviClear는 국제 시장에서 전년 대비 16% 성장했으며, 글로벌 핵심 자본은 전 분기 대비 7% 증가했습니다. 총 이익은 180만 달러(수익의 6%)로, 2023년 3분기의 650만 달러(14%)에서 감소했습니다. 운영 손실은 3천 620만 달러였습니다. 경영진은 연간 수익 전망을 1억 4천만에서 1억 4천 500만 달러로 재확인하였으며, 2024년 연말 현금 전망은 약 4천만 달러로 제시했습니다.
Cutera (CUTR) a publié les résultats financiers du troisième trimestre 2024 avec un chiffre d'affaires consolidé de 32,5 millions de dollars, représentant une baisse de 30 % par rapport au troisième trimestre 2023. L'entreprise a maintenu des liquidités et équivalents de 59,0 millions de dollars. AviClear a affiché une croissance de 16 % d'une année sur l'autre sur les marchés internationaux, tandis que le capital de base mondial a augmenté de 7 % d'un trimestre à l'autre. Le bénéfice brut s'élevait à 1,8 million de dollars (6 % du chiffre d'affaires), en baisse par rapport à 6,5 millions de dollars (14 %) au troisième trimestre 2023. La perte d'exploitation était de 36,2 millions de dollars. La direction a réaffirmé les prévisions de chiffre d'affaires pour l'année entière entre 140 et 145 millions de dollars, ainsi que la prévision de liquidités à la fin de 2024 d'environ 40 millions de dollars.
Cutera (CUTR) hat die finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlicht, mit einem konsolidierten Umsatz von 32,5 Millionen Dollar, was einem Rückgang von 30 % im Vergleich zum dritten Quartal 2023 entspricht. Das Unternehmen hielt Bargeld und Äquivalente in Höhe von 59,0 Millionen Dollar. AviClear zeigte ein Wachstum von 16 % im Jahresvergleich auf internationalen Märkten, während das globale Kernkapital im Quartalsvergleich um 7 % wuchs. Der Bruttogewinn betrug 1,8 Millionen Dollar (6 % des Umsatzes), ein Rückgang gegenüber 6,5 Millionen Dollar (14 %) im dritten Quartal 2023. Der operative Verlust betrug 36,2 Millionen Dollar. Das Management bekräftigte die Umsatzprognose für das gesamte Jahr von 140-145 Millionen Dollar und die Cash-Prognose zum Jahresende 2024 von etwa 40 Millionen Dollar.
- AviClear revenue growth of 16% year-over-year in international markets
- Global core capital growth of 7% quarter-over-quarter
- Management maintains full-year revenue guidance of $140-145 million
- Revenue decreased 30% year-over-year to $32.5 million
- Gross profit margin declined to 6% from 14% in Q3 2023
- Operating loss of $36.2 million in Q3 2024
- $10.1 million non-cash expense for excess inventory
- Cash position decreased from $84.3M to $59.0M quarter-over-quarter
Insights
The Q3 results reveal significant challenges at Cutera, with
The medical aesthetics market dynamics appear challenging for Cutera, with core metrics showing weakness. While AviClear showed
-
Consolidated revenue for the third quarter of 2024 of
$32.5 million -
Cash, cash equivalents, and restricted cash of
$59.0 million -
AviClear growth of
16% vs prior year period driven by international capital system sales -
Global core capital growth of
7% on a sequential quarterly basis - Full-year guidance maintained for both revenue and year-end cash balance
“Our third quarter reflects consistent execution against our strategic priorities, with core capital sales improving on a sequential basis, AviClear continuing to grow year-over-year driven by strong sales and utilization in international markets, and favorable underlying trends in our gross margin and operating expense profile,” commented Taylor Harris, Chief Executive Officer of Cutera, Inc. “We remain focused on expanding access to AviClear, our breakthrough technology for the treatment of acne, through training and education, practice development, and clinical indication expansion.”
Third Quarter 2024 Financial Highlights
Consolidated revenue for the third quarter of 2024 was
Gross profit was
Operating expenses were
GAAP operating loss was
Cash, cash equivalents, and restricted cash, were
2024 Outlook
Management is reaffirming full-year revenue guidance of
Conference Call
The Company’s management will host a conference call to discuss these results and related matters today at 1:30 p.m. PT (4:30 p.m. ET). Participating in the call will be Taylor Harris, Chief Executive Officer, Stuart Drummond, Interim Chief Financial Officer, and Shelby Eckerman, Vice President, Finance.
Participants can register for the conference call at this registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remain open until the end of the live conference call.
If participants prefer to dial in and speak with an operator, dial
The call will also be webcast and can be accessed from the Investor Relations section of Cutera’s website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
About Cutera, Inc.
Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. For over 25 years, Cutera has strived to improve lives through medical aesthetic technologies that are driven by science and powered through partnerships. For more information, call 1-888-4-CUTERA or visit Cutera.com.
*Use of Non-GAAP Financial Measures
In this press release, to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles (“GAAP”), management has disclosed certain non-GAAP financial measures for gross profit, gross margin rate, and income or loss from operations. Non-GAAP adjustments include depreciation and amortization including contract acquisition costs, stock-based compensation, enterprise resource planning (“ERP”) implementation costs, certain legal and litigation costs, costs associated with restructuring activities and the separation of its officers and other executives, gain on termination of a distribution agreement, and certain other adjustments. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure.
The Company defines non-GAAP operating income (loss), also commonly known as adjusted EBITDA, as operating income (loss) before depreciation and amortization, stock-based compensation, ERP implementation costs, certain legal and litigation costs, severance, gain on early termination of distribution agreement, and other adjustments.
Company management uses non-GAAP financial measures as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per share exclude the following:
Depreciation and amortization, including contract acquisition costs. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations;
Stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expenses related to grants of options, employee stock purchase plans, and performance and restricted stock. Depending upon the size, timing, and terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies;
ERP implementation costs. The Company has excluded ERP system costs related to direct and incremental costs incurred in connection with its multi-phase implementation of a new ERP solution and the related technology infrastructure costs. The Company excludes these costs because it believes that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency, making it difficult to contribute to a meaningful evaluation of the Company’s operating performance;
Certain legal and litigation costs. The Company has excluded costs incurred related to its litigation against Lutronic Aesthetics as well as the settlement of
Severance. The Company has excluded costs associated with restructuring activities and the separation of its officers and other executives in calculating its non-GAAP operating expenses and non-GAAP Operating Income. The Company has excluded restructuring costs because a restructuring represents a discrete event that signifies a change in the Company’s strategy, but these costs are not indicative of the ongoing financial performance of the business. The Company excludes executive separation costs because executive separations are unpredictable and not part of the Company’s business strategy but could have a significant impact on the results of operations;
Gain on early termination of distribution agreement. The Company has excluded a gain recorded in connection with the early termination of a distribution agreement with ZO
The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations. The Company no longer adjusts for costs related to a retention plan implemented in April 2023, as such costs represent a normal, recurring, operating cost, and accordingly, has not adjusted for
Safe Harbor Statement
Certain statements in this press release, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include but are not limited to express or implied statements regarding expanding access to AviClear, and full year revenues and cash, cash equivalents and restricted cash, along with other express or implied statements regarding Cutera’s plans, objectives, strategies, financial performance, guidance and outlook, product launches and performance, trends, prospects, or future events. In some cases, you can identify forward-looking statements by the use of words such as, but not limited to, “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management's current expectations and beliefs and are subject to risks and uncertainties, which are difficult to predict and may cause Cutera's actual results to differ materially from the express or implied forward-looking statements herein. These forward-looking statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond Cutera’s control, that could cause its actual results to differ materially from the forward-looking statements, including risks involved with continued expansion of AviClear, Cutera’s financial position and debt service requirements, and making financial projections, as well as the other risks described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.
All statements made in this release are made only as of the date set forth at the beginning of this release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If Cutera updates one or more forward-looking statements, no inference should be drawn that it will make additional updates concerning those or other forward-looking statements. Cutera's financial performance for the third quarter ended September 30, 2024, as discussed in this release, is preliminary and unaudited, and subject to adjustment.
CUTERA, INC. | |||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
(in thousands) | |||||||
(unaudited) | |||||||
September 30, | December 31, | ||||||
2024 |
2023 |
||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ |
57,614 |
|
$ |
143,612 |
|
|
Accounts receivable, net |
|
33,150 |
|
|
43,121 |
|
|
Inventories |
|
56,908 |
|
|
62,600 |
|
|
Other current assets and prepaid expenses |
|
12,842 |
|
|
19,852 |
|
|
Total current assets |
|
160,514 |
|
|
269,185 |
|
|
Long-term inventories |
|
28,664 |
|
|
16,283 |
|
|
Property and equipment, net |
|
23,521 |
|
|
37,275 |
|
|
Deferred tax asset |
|
590 |
|
|
579 |
|
|
Restricted cash |
|
1,363 |
|
|
- |
|
|
Goodwill |
|
1,339 |
|
|
1,339 |
|
|
Operating lease right-of-use assets |
|
10,593 |
|
|
10,055 |
|
|
Other long-term assets |
|
7,834 |
|
|
11,575 |
|
|
Total assets | $ |
234,418 |
|
$ |
346,291 |
|
|
Liabilities and Stockholders' Deficit | |||||||
Current liabilities: | |||||||
Accounts payable | $ |
7,949 |
|
$ |
19,829 |
|
|
Accrued liabilities |
|
35,972 |
|
|
55,055 |
|
|
Operating leases liabilities |
|
3,386 |
|
|
2,441 |
|
|
Deferred revenue |
|
8,382 |
|
|
10,422 |
|
|
Total current liabilities |
|
55,689 |
|
|
87,747 |
|
|
Deferred revenue, net of current portion |
|
1,689 |
|
|
1,494 |
|
|
Operating lease liabilities, net of current portion |
|
8,397 |
|
|
8,887 |
|
|
Convertible notes, net of unamortized debt issuance costs |
|
420,422 |
|
|
418,695 |
|
|
Other long-term liabilities |
|
1,095 |
|
|
1,298 |
|
|
Total liabilities |
|
487,292 |
|
|
518,121 |
|
|
Stockholders’ deficit: | |||||||
Common stock |
|
20 |
|
|
20 |
|
|
Additional paid-in capital |
|
136,929 |
|
|
131,496 |
|
|
Accumulated deficit |
|
(389,823 |
) |
|
(303,346 |
) |
|
Total stockholders' deficit |
|
(252,874 |
) |
|
(171,830 |
) |
|
Total liabilities and stockholders' deficit | $ |
234,418 |
|
$ |
346,291 |
|
CUTERA, INC. | |||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
(in thousands, except per share data) | |||||||||||||||
(unaudited) | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | September 30, | September 30, | ||||||||||||
2024 |
2023 |
2024 |
2023 |
||||||||||||
Products | $ | 27,242 |
|
$ | 40,989 |
|
$ | 88,714 |
|
$ | 146,285 |
|
|||
Service | 5,258 |
|
5,489 |
|
16,956 |
|
16,544 |
|
|||||||
Total net revenue | 32,500 |
|
46,478 |
|
105,670 |
|
162,829 |
|
|||||||
Products | 27,991 |
|
36,586 |
|
75,045 |
|
98,696 |
|
|||||||
Service | 2,696 |
|
3,435 |
|
8,749 |
|
9,961 |
|
|||||||
Total cost of revenue | 30,687 |
|
40,021 |
|
83,794 |
|
108,657 |
|
|||||||
Gross profit | 1,813 |
|
6,457 |
|
21,876 |
|
54,172 |
|
|||||||
Gross margin % | 5.6 |
% |
13.9 |
% |
20.7 |
% |
33.3 |
% |
|||||||
Operating expenses: | |||||||||||||||
Sales and marketing | 18,928 |
|
25,808 |
|
63,269 |
|
88,591 |
|
|||||||
Research and development | 4,353 |
|
4,592 |
|
13,817 |
|
16,844 |
|
|||||||
General and administrative | 14,749 |
|
17,004 |
|
31,951 |
|
47,448 |
|
|||||||
Gain on early termination of distribution agreement | - |
|
- |
|
(9,708 |
) |
- |
|
|||||||
Total operating expenses | 38,030 |
|
47,404 |
|
99,329 |
|
152,883 |
|
|||||||
Loss from operations | (36,217 |
) |
(40,947 |
) |
(77,453 |
) |
(98,711 |
) |
|||||||
Amortization of debt issuance costs | (580 |
) |
(561 |
) |
(1,726 |
) |
(1,670 |
) |
|||||||
Interest expense on convertible notes | (3,071 |
) |
(2,939 |
) |
(8,969 |
) |
(8,836 |
) |
|||||||
Interest income | 768 |
|
2,288 |
|
3,248 |
|
6,946 |
|
|||||||
Other expense (income), net | 575 |
|
(1,948 |
) |
(1,128 |
) |
(2,564 |
) |
|||||||
Loss before income taxes | (38,525 |
) |
(44,107 |
) |
(86,028 |
) |
(104,835 |
) |
|||||||
Income tax expense | 493 |
|
167 |
|
449 |
|
765 |
|
|||||||
Net loss | $ | (39,018 |
) |
$ | (44,274 |
) |
$ | (86,477 |
) |
$ | (105,600 |
) |
|||
Net loss per share: | |||||||||||||||
Basic | $ | (1.94 |
) |
$ | (2.22 |
) |
$ | (4.31 |
) |
$ | (5.32 |
) |
|||
Diluted | $ | (1.94 |
) |
$ | (2.22 |
) |
$ | (4.31 |
) |
$ | (5.32 |
) |
|||
Weighted-average number of shares used in per share calculations: | |||||||||||||||
Basic | 20,154 |
|
19,932 |
|
20,079 |
|
19,858 |
|
|||||||
Diluted | 20,154 |
|
19,932 |
|
20,079 |
|
19,858 |
|
CUTERA, INC. | ||||||||||||||||||||||
CONSOLIDATED FINANCIAL HIGHLIGHTS | ||||||||||||||||||||||
(in thousands, except percentage data) | ||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||
Three Months Ended | % Change | Nine Months Ended | % Change | |||||||||||||||||||
September 30, | September 30, | 2024 Vs | September 30, | September 30, | 2024 Vs | |||||||||||||||||
2024 |
2023 |
2023 |
2024 |
2023 |
2023 |
|||||||||||||||||
Revenue By Geography: | ||||||||||||||||||||||
$ | 14,651 |
|
$ | 24,855 |
|
-41.1 |
% |
$ | 49,150 |
|
$ | 84,494 |
|
-41.8 |
% |
|||||||
3,420 |
|
11,529 |
|
-70.3 |
% |
14,847 |
|
37,247 |
|
-60.1 |
% |
|||||||||||
Rest of World | 14,429 |
|
10,094 |
|
+42.9 | % |
41,673 |
|
41,088 |
|
+1.4 | % |
||||||||||
Total Net Revenue | $ | 32,500 |
|
$ | 46,478 |
|
-30.1 |
% |
$ | 105,670 |
|
$ | 162,829 |
|
-35.1 |
% |
||||||
International as a percentage of total revenue | 54.9 |
% |
46.5 |
% |
53.5 |
% |
48.1 |
% |
||||||||||||||
Revenue By Product Category: | ||||||||||||||||||||||
Systems | ||||||||||||||||||||||
- |
$ | 9,253 |
|
$ | 16,982 |
|
-45.5 |
% |
$ | 30,926 |
|
$ | 59,750 |
|
-48.2 |
% |
||||||
- Rest of World (including |
13,771 |
|
10,618 |
|
+29.7 | % |
40,258 |
|
41,654 |
|
-3.4 |
% |
||||||||||
Total Systems | 23,024 |
|
27,600 |
|
-16.6 |
% |
71,184 |
|
101,404 |
|
-29.8 |
% |
||||||||||
Consumables | 4,218 |
|
6,248 |
|
-32.5 |
% |
13,330 |
|
20,186 |
|
-34.0 |
% |
||||||||||
Skincare | - |
|
7,141 |
|
-100.0 |
% |
4,200 |
|
24,695 |
|
-83.0 |
% |
||||||||||
Total Products | 27,242 |
|
40,989 |
|
-33.5 |
% |
88,714 |
|
146,285 |
|
-39.4 |
% |
||||||||||
Service | 5,258 |
|
5,489 |
|
-4.2 |
% |
16,956 |
|
16,544 |
|
+2.5 | % |
||||||||||
Total Net Revenue | $ | 32,500 |
|
$ | 46,478 |
|
-30.1 |
% |
$ | 105,670 |
|
$ | 162,829 |
|
-35.1 |
% |
CUTERA, INC. | |||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||||||
(in thousands) | |||||||||||||||
(unaudited) | |||||||||||||||
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | September 30, | September 30, | ||||||||||||
2024 |
2023 |
2024 |
2023 |
||||||||||||
Cash flows from operating activities: | |||||||||||||||
Net loss | $ |
(39,018 |
) |
$ |
(44,274 |
) |
$ |
(86,477 |
) |
$ |
(105,600 |
) |
|||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||||||
Stock-based compensation |
|
1,841 |
|
|
1,616 |
|
|
5,543 |
|
|
6,552 |
|
|||
Depreciation and amortization |
|
1,669 |
|
|
1,987 |
|
|
5,464 |
|
|
5,225 |
|
|||
Amortization of contract acquisition costs |
|
1,113 |
|
|
3,016 |
|
|
3,882 |
|
|
7,085 |
|
|||
Amortization of debt issuance costs |
|
581 |
|
|
561 |
|
|
1,727 |
|
|
1,670 |
|
|||
Deferred tax assets |
|
(82 |
) |
|
19 |
|
|
(11 |
) |
|
62 |
|
|||
Provision for credit losses |
|
4,931 |
|
|
3,574 |
|
|
9,739 |
|
|
5,488 |
|
|||
Accretion of discount on investment securities and investment income, net |
|
- |
|
|
902 |
|
|
- |
|
|
1,048 |
|
|||
Changes in assets and liabilities: | |||||||||||||||
Accounts receivable |
|
(3,402 |
) |
|
276 |
|
|
232 |
|
|
(9,755 |
) |
|||
Inventories |
|
11,841 |
|
|
2,317 |
|
|
3,259 |
|
|
1,781 |
|
|||
Other current assets and prepaid expenses |
|
118 |
|
|
5,128 |
|
|
7,010 |
|
|
4,352 |
|
|||
Other long-term assets |
|
(142 |
) |
|
(860 |
) |
|
(472 |
) |
|
(5,642 |
) |
|||
Accounts payable |
|
(9,668 |
) |
|
(3,069 |
) |
|
(11,880 |
) |
|
(4,735 |
) |
|||
Accrued liabilities |
|
5,737 |
|
|
(7,157 |
) |
|
(18,704 |
) |
|
(10,963 |
) |
|||
Operating leases ,net |
|
(27 |
) |
|
(14 |
) |
|
(83 |
) |
|
(44 |
) |
|||
Deferred revenue |
|
(234 |
) |
|
(899 |
) |
|
(1,845 |
) |
|
(390 |
) |
|||
Net cash used in operating activities |
|
(24,742 |
) |
|
(36,877 |
) |
|
(82,616 |
) |
|
(103,866 |
) |
|||
Cash flows from investing activities: | |||||||||||||||
Acquisition of property and equipment |
|
(173 |
) |
|
(5,534 |
) |
|
(1,390 |
) |
|
(30,642 |
) |
|||
Proceeds from disposal of property and equipment |
|
- |
|
|
- |
|
|
63 |
|
|
- |
|
|||
Proceeds from maturities of marketable investments |
|
- |
|
|
41,044 |
|
|
193,903 |
|
||||||
Purchases of marketable investments |
|
- |
|
|
- |
|
|
- |
|
|
(23,467 |
) |
|||
Net provided by (used in) cash used in investing activities |
|
(173 |
) |
|
35,510 |
|
|
(1,327 |
) |
|
139,794 |
|
|||
Cash flows from financing activities: | |||||||||||||||
Proceeds from exercise of stock options and employee stock purchase plan |
|
- |
|
|
465 |
|
|
- |
|
|
1,323 |
|
|||
Taxes paid related to net share settlement of equity awards |
|
(26 |
) |
|
(87 |
) |
|
(110 |
) |
|
(3,273 |
) |
|||
Payments on finance lease obligation |
|
(393 |
) |
|
(149 |
) |
|
(582 |
) |
|
(386 |
) |
|||
Net cash provided by (used in) financing activities |
|
(419 |
) |
|
229 |
|
|
(692 |
) |
|
(2,336 |
) |
|||
Net increase (decrease) in cash, cash equivalents and restricted cash |
|
(25,334 |
) |
|
(1,138 |
) |
|
(84,635 |
) |
|
33,592 |
|
|||
Cash, cash equivalents, and restricted cash at beginning of period |
|
84,311 |
|
|
181,354 |
|
|
143,612 |
|
|
146,624 |
|
|||
Cash, cash equivalents, and restricted cash at end of period | $ |
58,977 |
|
$ |
180,216 |
|
$ |
58,977 |
|
$ |
180,216 |
|
CUTERA, INC. |
||||||||||||||
Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure |
||||||||||||||
(in thousands) |
||||||||||||||
Three Months Ended September 30, 2024 | Gross Profit | Gross Margin | Operating Expenses |
Operating Income |
||||||||||
Reported | $ |
1,813 |
|
5.6 |
% |
$ |
38,030 |
$ |
(36,217 |
) |
||||
Adjustments: | ||||||||||||||
Depreciation and amortization including contract acquisition costs |
|
1,643 |
|
5.1 |
% |
|
1,138 |
|
2,781 |
|
||||
Stock-based compensation |
|
102 |
|
0.3 |
% |
|
1,739 |
|
1,841 |
|
||||
Legal - Lutronic settlement |
|
- |
|
0.0 |
% |
|
- |
|
- |
|
||||
Severance |
|
189 |
|
0.6 |
% |
|
454 |
|
643 |
|
||||
Gain on early termination of distribution agreement |
|
- |
|
0.0 |
% |
|
- |
|
- |
|
||||
Other adjustments |
|
- |
|
0.0 |
% |
|
- |
|
- |
|
||||
Total adjustments |
|
1,934 |
|
6.0 |
% |
|
3,331 |
|
5,265 |
|
||||
Non-GAAP | $ |
3,747 |
|
11.5 |
% |
$ |
34,699 |
$ |
(30,952 |
) |
||||
Three Months Ended September 30, 2023 | Gross Profit | Gross Margin | Operating Expenses |
Operating Income |
||||||||||
Reported | $ |
6,457 |
|
13.9 |
% |
$ |
47,404 |
$ |
(40,947 |
) |
||||
Adjustments: | ||||||||||||||
Depreciation and amortization including contract acquisition costs |
|
2,371 |
|
5.1 |
% |
|
2,361 |
|
4,732 |
|
||||
Stock-based compensation |
|
(19 |
) |
0.0 |
% |
|
1,636 |
|
1,617 |
|
||||
ERP implementation cost |
|
- |
|
0.0 |
% |
|
1,456 |
|
1,456 |
|
||||
Legal - Lutronic expense |
|
- |
|
0.0 |
% |
|
561 |
|
561 |
|
||||
Severance |
|
151 |
|
0.3 |
% |
|
191 |
|
342 |
|
||||
Board of Directors legal and advisory fees |
|
- |
|
0.0 |
% |
|
1,280 |
|
1,280 |
|
||||
Other adjustments |
|
- |
|
0.0 |
% |
|
97 |
|
97 |
|
||||
Total adjustments |
|
2,503 |
|
5.4 |
% |
|
7,582 |
|
10,085 |
|
||||
Non-GAAP | $ |
8,960 |
|
19.3 |
% |
$ |
39,822 |
$ |
(30,862 |
) |
Nine Months Ended September 30, 2024 | Gross Profit | Gross Margin | Operating Expenses |
Operating Income |
||||||||||
Reported | $ |
21,876 |
20.7 |
% |
$ |
99,329 |
|
$ |
(77,453 |
) |
||||
Adjustments: | ||||||||||||||
Depreciation and amortization including contract acquisition costs |
|
5,564 |
5.3 |
% |
|
3,782 |
|
|
9,346 |
|
||||
Stock-based compensation |
|
395 |
0.4 |
% |
|
5,148 |
|
|
5,543 |
|
||||
Legal - Lutronic settlement |
|
- |
0.0 |
% |
|
(5,750 |
) |
|
(5,750 |
) |
||||
Severance |
|
285 |
0.3 |
% |
|
1,257 |
|
|
1,542 |
|
||||
Gain on early termination of distribution agreement |
|
- |
0.0 |
% |
|
(9,708 |
) |
|
(9,708 |
) |
||||
Other adjustments |
|
- |
0.0 |
% |
|
263 |
|
|
263 |
|
||||
Total adjustments |
|
6,244 |
5.9 |
% |
|
(5,008 |
) |
|
1,236 |
|
||||
Non-GAAP | $ |
28,120 |
26.6 |
% |
$ |
104,337 |
|
$ |
(76,217 |
) |
||||
Nine Months Ended September 30, 2023 | Gross Profit | Gross Margin | Operating Expenses |
Operating Income |
||||||||||
Reported | $ |
54,172 |
33.3 |
% |
$ |
152,883 |
|
$ |
(98,711 |
) |
||||
Adjustments: | ||||||||||||||
Depreciation and amortization including contract acquisition costs |
|
5,968 |
3.7 |
% |
|
6,342 |
|
|
12,310 |
|
||||
Stock-based compensation |
|
706 |
0.4 |
% |
|
5,847 |
|
|
6,553 |
|
||||
ERP implementation cost |
|
- |
0.0 |
% |
|
2,744 |
|
|
2,744 |
|
||||
Legal - Lutronic expense |
|
- |
0.0 |
% |
|
1,607 |
|
|
1,607 |
|
||||
Severance |
|
270 |
0.2 |
% |
|
621 |
|
|
891 |
|
||||
Board of Directors legal and advisory fees |
|
- |
0.0 |
% |
|
8,989 |
|
|
8,989 |
|
||||
Other adjustments |
|
307 |
0.2 |
% |
|
682 |
|
|
989 |
|
||||
Total adjustments |
|
7,251 |
4.5 |
% |
|
26,832 |
|
|
34,083 |
|
||||
Non-GAAP | $ |
61,423 |
37.7 |
% |
$ |
126,051 |
|
$ |
(64,628 |
) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107740612/en/
Cutera Investor Relations Contact:
Shelby Eckerman, VP, Finance
IR@Cutera.com
Source: Cutera, Inc.
FAQ
What was Cutera's (CUTR) revenue in Q3 2024?
How much did AviClear sales grow for Cutera (CUTR) in Q3 2024?
What is Cutera's (CUTR) full-year 2024 revenue guidance?